Mitochondrial haplogroup A2 is associated with increased COVID-19 mortality in an admixed Brazilian population.

Journal: Scientific reports
Published Date:

Abstract

Mitochondria play a crucial role in cellular respiration and immune responses. Mitochondrial DNA (mtDNA) haplogroups and variants have been associated with various diseases, including COVID-19. This study analyzed complete mtDNA sequences from 467 Brazilian patients with COVID-19 to investigate associations between mtDNA ancestry and mortality risk. Using classical statistical methods and a machine learning model, we identified key contributors to outcomes, with age as the primary risk factor, followed by male sex. Several mtDNA variants-663G, 1736G, 2706G, 3010A, 4248C, 4824G, 8027A, 8794T, and 10873C-were significantly associated with increased mortality risk. Most are characteristic of haplogroup A2, prevalent in populations with Native American ancestry. Notably, the 8027A allele, a non-synonymous substitution (Alanine > Threonine at position 148 of Cytochrome C Oxidase II), was predicted to be potentially damaging and emerged as the most significant marker. Rather than being disease-causing, these variants may amplify risk through interactions with other genetic, environmental, and clinical factors. Our findings emphasize that mtDNA variants and haplogroups are not phenotypically neutral and could serve as biomarkers of COVID-19 severity. Genetic studies prioritizing Indigenous populations and their descendants, who may be particularly susceptible to certain viruses, are urgently needed, especially given the predominant focus on European populations.

Authors

  • Gustavo Medina Tavares
    Laboratório de Evolução Humana e Molecular (LEHM), Programa de Pós-Graduação em Genética e Biologia Molecular (PPGBM), Departamento de Genética, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, 91501-970, Brazil. gmtavares@gmail.com.
  • Bruna Oliveira Missaggia
    Laboratório de Evolução Humana e Molecular (LEHM), Programa de Pós-Graduação em Genética e Biologia Molecular (PPGBM), Departamento de Genética, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, 91501-970, Brazil.
  • Nathan Araujo Cadore
    Laboratory of Genomic Medicine, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
  • Renan César Sbruzzi
    Laboratory of Genomic Medicine, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
  • Marilea Furtado Feira
    Laboratory of Genomic Medicine, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
  • Giovanna Câmara Giudicelli
    Laboratory of Genomic Medicine, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
  • Bibiana Sampaio de Oliveira Fam
    Laboratory of Genomic Medicine, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
  • Maira Rodrigues
    Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, SP, 05508-090, Brazil.
  • Márcio Dorn
    Federal University of Rio Grande do Sul, Institute of Informatics, Av. Bento Gonçalves 9500, 91501-970 Porto Alegre, RS, Brazil. Electronic address: mdorn@inf.ufrgs.br.
  • Tábita Hünemeier
    Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, SP, 05508-090, Brazil.
  • Fernanda Sales Luiz Vianna
    Laboratory of Genomic Medicine, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil. fvianna@hcpa.edu.br.
  • Maria Cátira Bortolini
    Laboratório de Evolução Humana e Molecular (LEHM), Programa de Pós-Graduação em Genética e Biologia Molecular (PPGBM), Departamento de Genética, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, 91501-970, Brazil. maria.bortolini@ufrgs.br.